Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Applied DNA Sciences (APDN)
NASDAQ:APDN
Holding APDN?
Track your performance easily
Earnings Data
Report Date
Feb 06, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
―Last Year’s EPS
―Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Dec 17, 2024
|% Change Since: -23.04%
|Next Earnings Date:Feb 06, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook with significant revenue decline and increased cash burn, alongside strategic advancements such as a new commercial agreement and the launch of a pharmacogenomic testing service. The company's progress towards GMP certification and a strengthened balance sheet are positive, but financial challenges, including Nasdaq compliance, remain pressing.Company Guidance
During the Applied DNA Sciences earnings call for the third quarter of fiscal 2024, several key metrics and guidance were provided. The company reported total revenues of approximately $798,000, reflecting a decline of $2.1 million from the same period in the prior fiscal year due to the conclusion of a COVID surveillance testing contract. Gross profit stood at $245,000, representing 31% of revenues, down from 44% the previous year. Operating expenses decreased by $500,000 to $3.6 million, driven by lower SG&A costs. Adjusted EBITDA was reported at negative $3.2 million, a decrease of $1.1 million year-over-year. Cash and cash equivalents totaled $10.4 million as of June 30, bolstered by a public offering that raised $10.5 million. Looking ahead, the company anticipates a revenue inflection in the first half of fiscal 2025, driven by expected developments in their biotherapeutics segment, including the Linea IVT platform, and ongoing business initiatives such as a new multiyear agreement within the cotton tagging market.Strengthened Balance Sheet
Cash and cash equivalents totaled $10.4 million on June 30, compared to $7.2 million on September 30, 2023, boosted by net proceeds of $10.5 million from a public offering.
GMP Facility On Track
The company is on track to complete its GMP facility by September 30, 2024, which will enhance its capacity for the enzymatic GMP production of DNA IVT templates.
New Commercial Agreements
A multiyear agreement with Indus Group was entered, potentially expanding the cotton tagging addressable market significantly.
Pharmacogenomic Testing Service Launch
TR8 PGx, a pharmacogenomic testing service, was launched commercially, with the company expecting it to approach profitability over the next two quarters.
---
APDN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
APDN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Dec 17, 2024 | $0.23 | $0.23 | 0.00% |
| Aug 08, 2024 | $0.35 | $0.36 | +2.86% |
| May 10, 2024 | $3.45 | $3.08 | -10.72% |
| Feb 08, 2024 | $12.00 | $12.20 | +1.67% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Applied DNA Sciences (APDN) report earnings?
Applied DNA Sciences (APDN) is schdueled to report earning on Feb 06, 2025, TBA Not Confirmed.
What is Applied DNA Sciences (APDN) earnings time?
Applied DNA Sciences (APDN) earnings time is at Feb 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is APDN EPS forecast?
Currently, no data Available
---